Peginterferon beta-1a has been recommended as a treatment option for relapsing remitting multiple sclerosis (RRMS) by The National Institute for Health and Care Excellence (NICE) for use on the NHS in England.
Injected under the skin every two weeks, the drug has been licenced for MS since 2014. There is clinical trial evidence to show it can slow disease progression and decrease the frequency of relapses compared with a placebo, and it needs to be injected less frequently than other beta interferons.
NICE said back in 2018 that it could not recommend the drug at that time after a review of several MS drugs, but it reversed this after a second appraisal.
For more information about access to this drug, please speak with your neurologist or MS nurse.
Source: MS-UK 21 February 2020